Viking Therapeutics and Roche both reported positive trial data on their obesity treatments. Shares of Viking Therapeutics surged in premarket trading, though paring initial gains. U.S. shares of Swiss drug giant Roche were not yet active. Weight-loss drug leaders Eli Lilly and Novo fell slightly. Viking Therapeutics (VKTX) reported that its GLP1/GIP agonist VK2735 delivered placebo-adjusted weight loss after 33…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: finance.yahoo.com
